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Abstract
Panic disorder (PD) occurs at greater rates among those with HIV compared to those without HIV. 
Rates of PD may be elevated among those with opioid dependence (persons who inject drugs, 
PWID). Persons with HIV experience common bodily symptoms as a result of the disease and 
these symptoms overlap with those of PD which may contribute to a “fear of fear” cycle present in 
PD. HIV-positive, PWID represent an at-risk population in terms of poor medication adherence. 
HIV symptoms and HIV medication side-effects commonly overlap with panic symptoms and 
may affect HIV medication adherence. The aim of this investigation was to examine the impact of 
PD on HIV-related symptom distress and HIV medication adherence in HIV-positive adults (N = 
131) in treatment for opioid use. Those with a diagnosis of PD evidenced greater levels of HIV 
symptom distress and lower levels of medication adherence than those without current PD. Results 
highlight the clinical importance of assessing for and treating PD among individuals with HIV that 
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are prescribed antiretroviral therapy. Future work would benefit from examining observed 
associations longitudinally and identifying potential mechanisms involved.
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Introduction
Compared to general population estimates, mood and anxiety disorders are highly prevalent 
and comorbid with one another among persons with HIV (Bing et al. 2001). While the study 
of depressive symptoms and disorders among those living with HIV has received significant 
theoretical and empirical attention (Ickovics et al. 2001; Leserman 2008), linking it with 
worse adherence to treatment and HIV outcomes, less work has been conducted examining 
the role of anxiety disorders in general, and panic disorder in particular.
Despite high rates panic disorder among those with HIV, there is little empirical 
investigation focused on how panic disorder might affect the management of HIV. Panic 
disorder (PD) is characterized by the misinterpretation of benign physical and cognitive 
sensations as serious and life-threatening (i.e., elevated heart rate, increased respiratory rate, 
loss of control), as well as anxious apprehension surrounding the possibility of future panic 
episodes (Barlow 2002). Among the general population, PD is responsible for substantial 
functional impairment (Kessler et al. 2006), poor quality of life (Barrera and Norton 2009), 
and reductions in perceived health (Gadermann et al. 2012). There are at least two clinically 
relevant reasons for studying PD among those with HIV. First, evidence suggests PD is 
more prevalent among those with compared to those without HIV (11–16 vs. 4–7 %, 
respectively; (Bing et al. 2001; Kessler et al. 2006). Second, persons with HIV experience 
common bodily symptoms as a result of the disease and medications used to treat HIV 
(Justice et al. 2001) and these symptoms significantly overlap with those of PD (e.g., 
dizziness, nausea) and may contribute to a “fear of fear” cycle present in PD.
PD may also play a substantial and clinically meaningful role in Antiretroviral Therapy 
(ART) adherence difficulties among those with HIV (Tsao et al. 2004). There is evidence 
suggesting a number of medical conditions are associated with high rates of PD compared to 
the general population including asthma (Goodwin and Eaton 2003), chronic obstructive 
pulmonary disease (Willgoss and Yohannes 2013), migraine (Smitherman et al. 2013), and 
spinal pain (Von Korff et al. 2005). Although rates of PD may be higher in certain medical 
conditions, little is understood as to how PD may specifically impact HIV disease 
management. In a nationally representative probability sample, PD was associated with 
greater odds (OR = 2.0) of non-adherence than non-psychiatric controls (Tucker et al. 2003). 
In a nationally representative sample of HIV-positive adults, PD was related to the 
experience of pain, after controlling for HIV disease stage (Tsao et al. 2004). It is important 
to further evaluate potential associations between PD and HIV symptom burden and ART 
adherence.
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Adherence to antiretroviral therapy (ART) is a vital component of successful viral 
suppression, delays in clinical progression, and decreased AIDS-related deaths 
(Emamzadeh-Fard et al. 2012; Garcia de Olalla et al. 2002; Low-Beer et al. 2000; Paterson 
et al. 2000). In addition, high ART adherence can decrease the risk for developing resistance 
to ART (Gardner et al. 2008; Kuritzkes 2004). Moreover, ART adherence may have 
important secondary HIV prevention implications: effective use of ART and attaining a 
suppressed viral load may reduce the likelihood of transmission of the virus (Cohen et al. 
2011; Del Romero et al. 2010; Donnell et al. 2010; Fisher et al. 2010).
The current study sought to evaluate PD with respect to HIV symptom distress and HIV 
medication adherence among patients with HIV and symptoms of depression in treatment 
for opioid dependence. The sample utilized for the current study is useful because the 
multimorbid psychiatric presentation is unfortunately common among persons living with 
HIV. Of note, HIV-positive drug users represent an already at-risk population in terms of 
poor medication adherence (Gonzalez et al. 2011, 2013; Justice et al. 2001) and individuals 
with substance dependence, including opioid dependence may be at elevated risk for PD 
(Grant et al. 2004; Martins et al. 2009). Additionally, opioid dependence has been 
specifically associated with poor ART adherence (Altice et al. 2010). It was hypothesized 
that those with a current diagnosis of PD, compared to those without current PD, would 
report greater HIV symptom distress and lower medication adherence, above and beyond 
potentially relevant demographic and clinical factors.
Method
Participants
Participants were 131 HIV-seropositive adults (53.4 % male; Mage = 46.73, SD = 7; see 
Table 1 for demographics) in treatment for opioid dependence. The majority of participants 
(70.3 %) were prescribed daily methadone. The racial breakdown of the sample was 42 % 
Caucasian, 29 % African American, 3.1 % Native American, one individual identified as 
Native Hawaiian/Pacific Islander and 22.1 % reported not identifying with the listed 
categories (i.e., “Other”). A substantial portion of the sample (30.8 %) identified their 
ethnicity as Hispanic/Latino. On average, participants reported 11.06 years (SD = 3.02) of 
educational attainment. Greater than two-thirds (68.8 %) of the sample had an undetectable 
viral load and the average CD4 t cell count was 442.82 (SD = 254.19).
Measures
The Miniature International Diagnostic Interview Schedule for Psychiatric Illness (MINI; 
Sheehan et al. 1998) was used to assess for current DSM-IV-TR psychological disorders, 
including current major depressive disorder. The MINI is a widely utilized measure of 
psychopathology that assesses diagnosis based on DSM-IV-TR criteria The MINI has 
evidenced adequate reliability and validity including concurrent validity with other 
diagnostic measures and is intended for lay-person administration (Sheehan et al. 1998). As 
part of this study, evaluation was completed by a clinical psychologist, master's level 
clinician, or doctoral student, and was presented for review and diagnostic consensus by the 
study team.
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Medication-Event-Monitoring-System (MEMS; AARDEX) caps were used to assess HIV 
medication adherence during a period of 2 weeks. MEMS caps are an electronic monitoring 
cap that fits onto a standard pill bottle and records each instance of bottle opening. We used 
this monitoring system to evaluate adherence to the ART medication that the participants 
considered the most difficult to remember or the dose taken most frequently. To account for 
doses that participants may have taken without opening the pill cap (e.g., took out afternoon 
doses when they opened the pill bottle in the morning), doses were counted as taken if 
participants could recall specific instances when they took their medications but did not use 
the cap. A dose was considered missed if it was not taken within a 2-h window of the 
designated time. The final adherence percentage represents the percent of doses taken on-
time over the 2-week period, corrected for times when participants took the medication but 
did not use the MEMS cap. These procedures, including using a 2-week monitoring period 
are common for measuring HIV medication adherence (Liu et al. 2006; Safren et al. 2009; 
Stirratt et al. 2006).
The AIDS Clinical Trials Group Symptom Distress Scale (ACTG; Justice et al. 2001) was 
used to measure distress related to HIV symptoms. Participants rated on a 5-point Likert-
type scale (0 = I do not have this symptom to 4 = It bothers me a lot) the extent to which 
each of 20 commonly experienced symptoms experienced with HIV (e.g., muscle aches, 
nausea) is bothersome. This scale has demonstrated excellent internal consistency 
(Cronbach α = .92) in previous work (Justice et al. 2001). To reduce HIV-related symptom 
overlap with PD we removed five items that assess panic symptoms (i.e, “Fevers, chills or 
sweats”; “Feeling dizzy or lightheaded”, “Pain, numbness or tingling in the hands or feet”, 
“Felt nervous or anxious”, and “Cough or trouble catching your breath”). The remaining 
15items demonstrated acceptable internal consistency (Cronbachs α = .73).
Procedure
Participants were recruited from methadone clinics in the greater Boston area and through 
community outreach and hospital-based HIV clinics. Individuals were recruited for a study 
of adherence to HIV medications for adults in treatment for opioid dependency, whether or 
not they self-reported problems with medication adherence or depression. Inclusion criteria 
included being between age 18 and 65, HIV-sero-positive, prescribed antiretroviral therapy 
for HIV, endorsed a history of injection drug use, and were currently enrolled in treatment 
for opioid abuse or dependence for at least 1 month. Informed consent procedures and 
baseline assessments were conducted over two study visits that consisted of an assessment 
battery, a clinical psychiatric interview, an oral toxicology screen, and blood-draw. At the 
first baseline visits, participants were given a MEMS cap to monitor their HIV medication 
adherence for a 2-week period, which they returned at the second study visit prior to 
randomization into one of the two study arms. Participants were compensated $50 for their 
time and participation. Data for the current analyses was collected from all participants 
completing baseline procedures for the larger randomized controlled trial prior to treatment 
randomization and initiation (Safren et al. 2012).
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Data Analytic Strategy
Descriptive statistics were first examined for demographic and study variables. Hierarchical 
regression analyses were conducted with HIV symptom distress and percentage of 2-week 
HIV medication adherence as the criterion variables. At step 1 of each model, the main 
effects of age, sex, number of years of education, and a dichotomous variable for major 
depressive disorder (MDD) status (0 = no MDD and 1 = MDD) were entered as potential 
covariates. These covariates were chosen on an a priori basis because previous work 
indicates relations with ART adherence (Gay et al. 2011; Hinkin et al. 2004; Puskas et al. 
2011; Turner et al. 2003). Specifically, we included MDD as a covariate for two reasons: (1) 
past work indicates depressive symptoms are associated with poor medication adherence 
(Gonzalez et al. 2011) and (2) over half the sample screened positive for current major 
depressive disorder. At step 2, a dichotomous variable for PD status (0 = no PD and 1 = PD) 
was entered. To assess for the specificity of relationships with respect to PD, we then 
separately reran the models accounting for social anxiety disorder, and generalized anxiety 
disorder using dichotomous variables. Due to technical problems with the electronic pill 
caps, ART adherence data (MEMS) was not usable for five participants, reducing the sample 
size for relevant analyses to N = 126.
Results
Descriptive Data and Psychopathology
See Table 1 for correlations among theoretically relevant variables. The average 2-week 
HIV medication adherence for the sample was 68.12 % (SD = 28.8), as measured by 
Medication Event Monitoring System (MEMS) caps. In terms of anxiety disorders, 29.8 % 
of the sample evidenced a single current anxiety disorder as assessed by the MINI. 
Additionally, 18.3 % met criteria for two co-occurring anxiety disorders. Twenty-nine 
percent of the sample met criteria for a current primary diagnosis (i.e., disorder rated most 
severe or impairing) of PD. A total of 55 % of the sample met criteria for current major 
depressive disorder, 14.5 % of the sample met criteria for generalized anxiety disorder, 11.5 
% met criteria for obsessive–compulsive disorder and 22.9 % met criteria for social anxiety 
disorder.
Hierarchical Regression Analyses
See Table 2 for regression analyses. For HIV symptom distress, the overall model accounted 
for 6.0 % of variance. At step 1, the control variables did not make a significant contribution 
to the model (R2 = .02). At step 2, PD status accounted for an additional 4.0 % of the 
variance and was a significant, positive predictor of HIV symptom distress (β = .20, p = .04).
For medication adherence, the overall model accounted for 9.0 % of variance. At step 1, the 
control variables did not make a significant contribution to the model (R2 = .04). At step 2, 
PD status accounted for an additional 5 % of the variance and was a significant, negative 
predictor of medication adherence (β = −.24, p = .02).
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In follow-up analyses, the relationship between PD and HIV symptom distress and 
medication adherence remained significant after controlling for social anxiety disorder and 
generalized anxiety disorder independently, in separate models.
Discussion
This is the first study, of which we are aware, showing that current PD diagnosis is 
associated with greater HIV symptom distress and reduced ART medication adherence in 
adults with HIV managing opioid dependence. These associations were observed after 
accounting for a current major depression diagnosis, as well as two other prevalent anxiety 
disorders: social anxiety disorder and generalized anxiety disorder.
Elevated rates of PD among individuals with HIV (Bing et al. 2001) and those with opioid 
dependence have been documented (Martins et al. 2009). In line with past findings, the 
prevalence of current PD was markedly high in this sample, with 29 % of participants 
positively assessed for a current, primary diagnosis of PD; a figure approximately tenfold 
higher than that documented in the general population (Kessler et al. 2005a). Negative 
effects of PD on social and occupational functioning have been established in the general 
population (Kessler et al. 2005b). However, little is known about the effects of PD on living 
with and managing HIV and opioid dependence. The current results build on this previous 
work (Gonzalez et al. 2012) and indicate a potentially unique role for PD in HIV symptom 
distress and medication adherence in this multiply challenged sample.
Only recently has research begun to explicate potential cognitive mechanisms between PD 
and HIV. Cognitive factors implicated in PD such as anxiety sensitivity may play a 
contributing role in the observed relationships. Anxiety sensitivity, conceptualized as the 
fear of anxiety-related sensations, is an established cognitive risk and maintenance factor for 
PD (Ehlers 1995) and is associated with HIV-symptom distress (Gonzalez et al. 2012). In 
addition, Gonzalez et al. (2012) found that HIV symptom distress is related to PD symptoms 
in the context of elevated anxiety sensitivity. Specifically, side effects of HIV and 
medications used to treat the virus commonly overlap with panic symptoms. Those with PD 
or elevated AS may be particularly at risk for misinterpreting HIV symptoms or symptoms 
of opioid withdrawal as anxiety provoking, resulting in both increased anxiety-related 
symptom distress and poor medication adherence in an effort to avoid distressing 
medication-related side effects.
Although limited work has documented elevated rates of PD among individuals with opioid 
dependence (Gros et al. 2013), research is needed to examine potential underlying 
mechanisms of this relation, such as the role of acute opioid withdrawal and cognitive 
vulnerability factors (i.e., AS) as noted previously. Initial work supports a relation between 
opioid use and elevated AS (Lejuez et al. 2006). Of note, the majority of individuals in the 
current sample were receiving treatment(s) to maintain abstinence, which may reduce the 
impact of acute opioid withdrawal symptoms on observed associations. In addition, we have 
made efforts to account for variables of theoretical and empirical relevance in the models 
presented but it is plausible that additional factors unique to opioid dependence treatment 
may be contributing to the observed relationships (e.g., side effects of methadone treatment). 
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Thus, the current findings should be viewed within this context. Future work would benefit 
from assessing observed relationships at multiple times during the course of opioid 
treatment (i.e., initiation, dropout).
Further investigations are warranted to parse apart observed relationships and elucidate 
directionality of these findings. Specifically, the analyses presented here are cross-sectional 
in nature; therefore neither causality nor directionality of the relationships can be 
determined. Future research would benefit from examining these associations longitudinally, 
by manipulating the variables of interest (i.e., treating PD) to evaluate the potential 
secondary effects on HIV specific distress and adherence or as mediators of treatment 
outcome, and assessing panic attack history and frequency. Although we attempted to 
account for the potential influence of major depressive disorder, the effects of major 
depression or subsyndromal depression cannot be completely ignored. In particular, 
depression severity and history was not explored.
The measure of HIV symptom distress was modified for these analyses to reduce the risk of 
construct overlap with PD but resulted in lower internal consistency relative to previous 
studies (Marc et al. 2012). Lastly, PD accounted for a statistically significant effect, though 
the portion of overall variance in HIV symptom distress and medication adherence was 
modest. It will be important to replicate analyses in broader samples of HIV-positive adults, 
including those not managing opioid use and to investigate other factors that might reduce 
adherence (e.g., neurocognitive deficits; Zogg et al. 2012).
The results presented here provide incremental evidence for specific and clinically important 
effects of PD in individuals with multiple competing and chronic psychological and physical 
health conditions. These results underscore the impact and importance of assessing for and 
treating PD in persons with HIV managing opioid use and point to the importance of 
developing flexible treatment platforms capable of addressing multiple comorbid mental 
health problems in this patient group.
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